Evidences showed that short-term intensive insulin treatment in patients with newly diagnosed type 2 diabetes mellitus induced long-term drug-free remission in virtue of rapid elimination of hyperglucotoxicity, as well as restoration of first phase insulin secretion. Our previous studies also showed that type 2 diabetic patients who were inadequately controlled with multiple oral hypoglycemic agents and/or poorly responded to insulin supplement treatment were also benefited from short-term intensive insulin therapy. Near normoglycemic control achieved by aggressive insulin treatment allowed beta cell rest, thus led to further restoration of beta cell function, which availed a simplified subsequent treatment plan. Optimization of short-term intensive insulin treatment is required to achieve the glycemic goal rapidly and safely, thus improving patients’ outcome. Herein, I will share with you our experience in picking the right patients, setting the stringent glycemic goal, individualizing total insulin dosage as well as the desirable allocation of basal and bolus insulin, making a timely adjustment of the dosages, and close monitoring and following glucose level, all of which are the keys to the success of the short-term intensive insulin treatment.